

UCB IN THE UK & IRELAND

OUR CORE BELIEF

At UCB, our core belief has remained constant for almost a century

Everyone deserves to live the best life that they can, **AS FREE AS POSSIBLE** from the challenges and uncertainty of severe disease.

We put **PATIENTS AT THE CENTRE OF EVERYTHING WE DO**. We listen with intent and make bold choices to pursue what's right for them.

We are a leading investor in the UK and are committed to delivering excellence in **FOUR KEY AREAS**:

- 1 RESEARCH & DEVELOPMENT
- 2 PATIENTS
- 3 PEOPLE
- 4 SUSTAINABILITY



RESEARCH & DEVELOPMENT (R&D)

Our scientists harness evidence-based science to deliver treatments and personalised services that address **patient needs**.

We have world-class discovery, research, development and early manufacturing facilities, and consistently **reinvest around a quarter of our revenue** back into R&D.

We have announced a **£1 billion** investment, including a **new science hub** in Windlesham, Surrey.

Since 2013, UCB has initiated **97 trials** across **1,312 trial sites** involving **2,476 UK patients**.

PATIENTS

We support patients in overcoming the burdens of their disease, **helping them live their best possible lives**.




We have **collaborated closely with patients** and stakeholders to create digital solutions that aim to increase adherence and symptom tracking, and monitor disease progression.

We are **driving change** in clinical trials to meet patient needs.

We are **committed to being a partner to the NHS** and we recognise the importance of working together to **deliver innovative solutions** that benefit patients.

PEOPLE

We inspire a **culture of inclusion** by providing opportunities to all current and prospective employees.



Around 10% of UCB's global workforce are **employed across the UK and Ireland**.

We focus on offering career opportunities to all, **embracing unique talents**.

We aim to increase knowledge and interest in careers across Science, Technology, Engineering and Maths (STEM), and **create opportunities for all in science**.



SUSTAINABILITY

How we do business is important to us; we plan to deliver **sustainable business growth** and contribute to **positive societal impact**.

In the countries we operate in, our goal is that **all patients** who need our medicines will have **access to them by 2030**.

WE AIM TO REACH NET-ZERO BY 2045 BY:

Reducing our Scope 1, 2 and 3 emissions by **90%**.

Neutralising all remaining greenhouse gas emissions.



INSPIRED BY PATIENTS. DRIVEN BY SCIENCE.



Whether in the **treatments we develop**, or in how we deliver those treatments, **patient input is one of the main drivers behind our decisions**. This is how we can continue to innovate with agility and purpose, to pursue what's right for those who live with severe diseases.

